Literature DB >> 16156852

Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.

Dimitri A Breems1, Bob Löwenberg.   

Abstract

Most adult patients under 60 years with acute myeloid leukaemia (AML) who achieve a complete remission after induction chemotherapy will relapse if they do not receive further therapy. Consolidation treatment with autologous stem cell transplantation (SCT) is one option that has been studied extensively. High-dose cytotoxic therapy followed by autologous SCT or intensive cycles of chemotherapy furnish overall approximately similar probabilities of survival when applied in first remission. Here, we present a concise update regarding the place of autologous SCT in the treatment of AML. Particular issues discussed are the value of autologous SCT in different prognostic subsets of AML and the value of autologous mobilised peripheral blood stem cell transplants, which offer a much faster haematopoietic recovery.

Entities:  

Mesh：

Year:  2005        PMID： 16156852     DOI： 10.1111/j.1365-2141.2005.05628.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  6 in total

1.  NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

Authors:  Mobin A Karimi; Jerrod L Bryson; Lee P Richman; Andrew D Fesnak; Theresa M Leichner; Atsushi Satake; Robert H Vonderheide; David H Raulet; Ran Reshef; Taku Kambayashi
Journal:  Blood       Date:  2015-03-18       Impact factor: 22.113

Review 2.  Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

Authors:  Abraham S Kanate; Marcelo C Pasquini; Parameswaran N Hari; Mehdi Hamadani
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

3.  Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.

Authors:  James M Foran; Steven Z Pavletic; Brent R Logan; Manza A Agovi-Johnson; Waleska S Pérez; Brian J Bolwell; Martin Bornhäuser; Christopher N Bredeson; Mitchell S Cairo; Bruce M Camitta; Edward A Copelan; Jason Dehn; Robert P Gale; Biju George; Vikas Gupta; Gregory A Hale; Hillard M Lazarus; Mark R Litzow; Dipnarine Maharaj; David I Marks; Rodrigo Martino; Richard T Maziarz; Jacob M Rowe; Philip A Rowlings; Bipin N Savani; Mary Lynn Savoie; Jeffrey Szer; Edmund K Waller; Peter H Wiernik; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-28       Impact factor: 5.742

4.  Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.

Authors:  Mahinbanu Mammadli; Weishan Huang; Rebecca Harris; Hui Xiong; Samuel Weeks; Adriana May; Teresa Gentile; Jessica Henty-Ridilla; Adam T Waickman; Avery August; Alaji Bah; Mobin Karimi
Journal:  iScience       Date:  2021-03-11

5.  Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.

Authors:  Mahinbanu Mammadli; Weishan Huang; Rebecca Harris; Aisha Sultana; Ying Cheng; Wei Tong; Jeffery Pu; Teresa Gentile; Shanti Dsouza; Qi Yang; Alaji Bah; Avery August; Mobin Karimi
Journal:  Front Immunol       Date:  2020-11-26       Impact factor: 7.561

6.  Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia.

Authors:  Gert J Ossenkoppele; Jeroen Jwm Janssen; Peter C Huijgens
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-02-16       Impact factor: 2.576
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.